Medacta Group SA

2022 Full Year Unaudited Top-Line Figures release / Today's call at 4:00pm CET - Seite 2

Revenue by geography and product line

2022 shows strong growth in all geographies, with the strongest growth rate in Europe, where revenue registered an increase of 17.6% on a constant currency basis to Euro 187.4 million. The growth was driven by customer acquisition, together with normalization of surgical activities.

Revenue in North America increased to Euro 136.8 million, or 11.5% on a constant currency basis, thanks to our customer acquisition, which was limited by the impact of Covid-19 and hospital staffing shortages especially in the first months of the year.

Asia Pacific grew by 11.2% on a constant currency basis to Euro 94.4 million, mainly driven by the attainment of new customers in Japan. Australia was limited by significant longer than expected COVID impact, with recovery only in the last months of the year.

RoW registered revenue for Euro 18.6 million, an increase of 38.7% on a constant currency basis, mainly thanks to increased purchases from stocking distributors in Latin America.

Below we report the FY 2022 sales break-down by geographic area:

(Million Euro)	FY 2022 (€M)	FY 2021 (€M)	Reported Growth (%)	Constant Currency Growth (%)
Europe	187.4	156.4	19.8%	17.6%
North America	136.8	109.2	25.2%	11.5%
Asia Pacific	94.4	84.9	11.1%	11.2%
RoW*	18.6	12.6	48.1%	38.7%
TOTAL	437.1	363.1	20.4%	15.0%
* RoW includes all other geographic locations, including Middle East.

Revenue from our Hip products increased to Euro 203.6 million, or 9.2% on a constant currency basis; the good momentum was driven by the AMIS strategy and roll-out of new products in the revision segment.